PAS
TAK icon

Park Avenue Securities’s Takeda Pharmaceutical TAK Stock Holding History

Park Avenue Securities’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$719K Sell
44,827
-996
-2% -$16.5K ﹤0.01% 1112
2026
Q1 		$849K Buy
45,823
+8,139
+22% +$143K 0.01% 887
2025
Q4 		$587K Buy
37,684
+4,662
+14% +$66.7K 0.01% 1025
2025
Q3 		$483K Sell
33,022
-1,341
-4% -$19.9K ﹤0.01% 1201
2025
Q2 		$531K Buy
34,363
+2,535
+8% +$37.5K ﹤0.01% 1039
2025
Q1 		$473K Buy
31,828
+4,177
+15% +$58.5K 0.01% 874
2024
Q4 		$366K Buy
27,651
+6,094
+28% +$83.7K ﹤0.01% 1199
2024
Q3 		$307K Sell
21,557
-6,670
-24% -$94.6K ﹤0.01% 1172
2024
Q2 		$365K Sell
28,227
-617
-2% -$8.17K ﹤0.01% 1111
2024
Q1 		$401K Sell
28,844
-2,897
-9% -$42.1K 0.01% 1061
2023
Q4 		$453K Sell
31,741
-5,736
-15% -$81.4K 0.01% 953
2023
Q3 		$580K Buy
37,477
+10,255
+38% +$159K 0.01% 780
2023
Q2 		$428K Buy
27,222
+2,001
+8% +$32.8K 0.01% 642
2023
Q1 		$416K Buy
25,221
+1,268
+5% +$20.2K 0.01% 626
2022
Q4 		$374K Buy
23,953
+3,507
+17% +$49K 0.01% 886
2022
Q3 		$265K Buy
20,446
+1,197
+6% +$16.6K 0.01% 956
2022
Q2 		$270K Buy
19,249
+3,708
+24% +$52.9K 0.01% 960
2022
Q1 		$223K Buy
15,541
+2,893
+23% +$42.5K ﹤0.01% 1057
2021
Q4 		$172K Buy
12,648
+280
+2% +$3.93K ﹤0.01% 1078
2021
Q3 		$203K Sell
12,368
-336
-3% -$5.64K ﹤0.01% 993
2021
Q2 		$214K Buy
12,704
+344
+3% +$5.86K ﹤0.01% 968
2021
Q1 		$226K Buy
12,360
+1,539
+14% +$27.7K 0.01% 884
2020
Q4 		$197K Buy
+10,821
New +$190K 0.01% 819

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Park Avenue Securities's TAK Position: Q2 2026 in Review

Park Avenue Securities reduced its Takeda Pharmaceutical (TAK) stake by 2.2% in Q2 2026, selling an estimated $16.5K and leaving 44,827 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

Park Avenue Securities first reported a position in TAK in Q4 2020 and has held it in 23 quarters since. The position peaked at $849K in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Park Avenue Securities held 44,827 shares of Takeda Pharmaceutical worth $719K as of Q2 2026.
  • Park Avenue Securities sold 996 Takeda Pharmaceutical shares in Q2 2026, an estimated $16.5K.
  • Takeda Pharmaceutical made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1112 holding.
  • Park Avenue Securities first reported a position in Takeda Pharmaceutical in Q4 2020 and has held it in 23 quarters since.
  • Park Avenue Securities's Takeda Pharmaceutical position peaked at $849K in Q1 2026.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.